A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy

A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy

Abstract CC Chemokine Receptor 2 (CCR2) and its endogenous ligand CCL2 are involved in a number of diseases, including atherosclerosis. Several CCR2 antagonists have been developed as potential therapeutic agents, however their in vivo clinical efficacy was limited. In this report, we aimed to deter...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ilze Bot, Natalia V. Ortiz Zacarías, Wilhelmus E. A. de Witte, Henk de Vries, Peter J. van Santbrink, Daniël van der Velden, Mara J. Kröner, Dirk-Jan van der Berg, Dean Stamos, Elizabeth C. M. de Lange, Johan Kuiper, Adriaan P. IJzerman, Laura H. Heitman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/be41579bc6074a96b13bbf8097e120c1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/be41579bc6074a96b13bbf8097e120c1

Ejemplares similares